PT-141 in women: how bremelanotide works, dosing, and side effects

Last updated 2026-07-24

What is PT-141 and how does it work in women?

PT-141 (bremelanotide) is a synthetic peptide that acts on melanocortin receptors in the central nervous system. The FDA approved it in June 2019 as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women ^[1]. It's the second FDA-approved drug for this indication, after flibanserin, and the first delivered by self-injection rather than daily pill. The mechanism is fundamentally different from drugs like sildenafil (Viagra). PT-141 doesn't increase blood flow to the genitals. It binds to melanocortin MC3 and MC4 receptors in the hypothalamus and other brain regions that regulate sexual response ^[2]. This central action modulates neural circuits for desire, arousal, and reward. The hypothesis is that HSDD reflects an imbalance between excitatory and inhibitory pathways in the brain, and melanocortin signaling tips that balance toward excitation ^[3]. The drug was originally developed and tested intranasally for both men and women, but cardiovascular concerns (transient blood pressure spikes) led to development of the subcutaneous formulation for women only. The approved product delivers 1.75 mg in a single-dose autoinjector pen ^[4]. Branding: the generic name bremelanotide and the trade name Vyleesi both refer to the same molecule. PT-141 is the research designation used in early studies. All three terms appear in the literature and online discussion.

How effective is PT-141 for women with low sexual desire?

Two phase 3 trials (RECONNECT studies) enrolled 1,247 premenopausal women with HSDD and randomized them to bremelanotide 1.75 mg or placebo, self-administered as needed before sexual activity, for 24 weeks ^[5]. The primary endpoints were change in desire (measured by the Female Sexual Function Index desire domain) and change in distress (measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm item 13). Bremelanotide produced statistically significant improvements on both endpoints compared to placebo. The mean change in desire score from baseline was roughly 0.3 to 0.4 points higher with bremelanotide than placebo (on a 6-point scale). The mean change in distress score was approximately 0.2 to 0.3 points better (on a 5-point scale). Both differences reached p < 0.001 ^[5]. Those numbers sound small because the scales are narrow. A responder analysis gives a clearer picture: 24.5% of bremelanotide users had a clinically meaningful improvement (defined as ≥ 0.6-point increase in desire and ≥ 0.4-point decrease in distress), versus 17.0% of placebo users ^[6]. So about 1 in 4 women on bremelanotide saw a meaningful benefit, compared to 1 in 6 on placebo. That's a number needed to treat of roughly 13. A phase 2b dose-ranging study tested 0.75 mg, 1.25 mg, and 1.75 mg against placebo. All three doses showed numerical improvement over placebo, but 1.75 mg had the best balance of efficacy and tolerability, leading to its selection for phase 3 ^[6]. Higher doses were not tested in the registration trials. Subgroup analyses found similar effect sizes across age ranges (18-40 vs. over 40), menopausal status (premenopausal vs. postmenopausal, though the drug is only approved in premenopausal women), baseline BMI, and whether HSDD was acquired or lifelong ^[7]. That consistency suggests the mechanism is not highly dependent on hormonal or demographic factors. A reanalysis of the phase 3 data pointed out that the effect size (Cohen's d) for the desire endpoint was small (d ≈ 0.22) and that the clinical significance of sub-one-point shifts on these scales is debatable ^[8]. The authors argued that the difference, while statistically solid, may not be large enough to matter in everyday life for many women. Critics noted high placebo response rates (about 35% on some measures), which is typical in sexual dysfunction trials but makes modest drug effects harder to interpret ^[9].

What are the most common side effects of PT-141 in women?

Nausea is the most frequent adverse event. In the pooled phase 3 trials, 40.0% of bremelanotide users reported nausea versus 12.5% on placebo ^[10]. Most nausea was mild to moderate and occurred within two hours of injection. In the integrated safety analysis across all clinical studies, nausea led to discontinuation in about 4% of participants ^[10]. Flushing (redness and warmth of the face, neck, or chest) occurred in 20.3% of bremelanotide users versus 2.8% on placebo ^[10]. Like nausea, flushing typically appeared within a couple of hours and resolved on its own. Injection-site reactions (redness, bruising, pain at the injection site) were reported by roughly 13% of users ^[4]. These were generally mild and transient. Headache, vomiting, and nasal congestion each occurred in a few percent more women on bremelanotide than placebo. Hyperpigmentation (darkening of the skin or gums) was rare in the trials but has been observed with other melanocortin agonists and is listed as a potential risk in the prescribing information ^[4]. Cardiovascular effects: blood pressure can rise transiently after injection. In phase 3, systolic BP increased by a mean of about 2-3 mm Hg in the hours following administration ^[10]. A small percentage of women had BP spikes above 180/110 mm Hg. Women with uncontrolled hypertension were excluded from the trials, and the drug is not recommended for women with cardiovascular disease ^[11]. If you're managing high blood pressure with medication, discuss PT-141 with your cardiologist or primary care provider before using it. Skin darkening deserves a separate mention. Melanocortin receptors regulate melanocyte activity (the cells that produce pigment). Chronic use of high-dose melanocortin agonists can cause hyperpigmentation, especially in areas already rich in melanocytes (gums, areolae, existing moles). None of the phase 3 trial participants developed clinically significant hyperpigmentation ^[10], but the labeling advises monitoring for darkening of skin or mucous membranes. If you notice new pigmentation that doesn't fade, bring it up with your provider. For sourcing and fulfillment options, pt-141 peptide therapy near me and best place to buy pt 141 walk through provider-reviewed pathways and pharmacy partners.

How do you dose PT-141 for women, and how quickly does it work?

The FDA-approved dose is 1.75 mg subcutaneous, injected into the abdomen or thigh at least 45 minutes before anticipated sexual activity ^[4]. You inject only when you're planning to be sexually active, not daily. Maximum frequency is one dose per 24 hours and no more than eight doses per calendar month. The 45-minute window reflects the drug's pharmacokinetics. Peak plasma concentration occurs around 60 minutes after injection ^[12]. Women in the trials were instructed to inject 45 to 60 minutes before they expected sexual activity, though some reported effect as early as 30 minutes and others noticed a benefit lasting several hours ^[5]. You inject subcutaneously (into the fat layer under the skin, not into muscle). The approved Vyleesi autoinjector pen delivers the full 1.75 mg dose with a single click. If you're using a compounded version from a 503A or 503B pharmacy, you'll draw the dose into a standard insulin syringe (typically a small volume, around 0.1 to 0.2 mL depending on the concentration). Rotate injection sites to avoid irritation. Duration of action is not precisely defined. The drug's half-life is about 2 to 3 hours ^[12], but subjective effects (desire, arousal) can persist longer, likely because receptor binding and downstream signaling outlast the drug's presence in the blood. Some women use it earlier in the evening, knowing the effect will carry into the night. There's no titration schedule. You start at 1.75 mg. Lower doses (0.75 mg, 1.25 mg) were tested in phase 2 and showed weaker effects ^[6]. Higher doses were not pursued in phase 3 because nausea and flushing increased at 2.0 mg and above in early studies. Skip the dose if you're feeling nauseated or have an active infection. The prescribing information doesn't list specific contraindications beyond uncontrolled hypertension and known cardiovascular disease, but common sense says if you're already unwell, adding a drug that frequently causes nausea is a bad idea. For discussion of monitoring and lab work, see pt-141 and blood work.

Does PT-141 work in postmenopausal women?

The FDA approval is limited to premenopausal women, but both phase 3 trials included postmenopausal women in exploratory subgroups (about 20% of the total sample) ^[7]. The subgroup analysis found similar effect sizes for desire and distress improvements in postmenopausal women compared to premenopausal women. The sample was too small to draw firm conclusions, but the signal was encouraging. The narrower approval reflects regulatory conservatism, not evidence of harm or futility in postmenopausal women. HSDD is more common after menopause, and the pathophysiology (central dysregulation of desire circuits) doesn't obviously hinge on ovarian hormone levels. The melanocortin system operates independently of estrogen and progesterone, though those hormones do modulate sexual response through parallel pathways ^[13]. Off-label use in postmenopausal women happens in clinical practice. If you're postmenopausal and interested, bring the subgroup data to your provider. They can prescribe off-label if they judge it appropriate. Compounded bremelanotide from a 503A pharmacy (prescribed for an individual patient) or a 503B outsourcing facility (larger-scale compounding) is one pathway; the branded Vyleesi autoinjector is another, though insurance coverage may be narrower for off-label indications. No studies have directly compared premenopausal and postmenopausal cohorts head-to-head with adequate power. The question remains open.

Can PT-141 be combined with other treatments for low desire?

The phase 3 trials did not test combination therapy, so there's no direct evidence on adding PT-141 to flibanserin, testosterone, or psychotherapy. But the mechanisms are distinct enough that additive effects are plausible. Flibanserin works via serotonin (5-HT1A agonism and 5-HT2A antagonism) and dopamine pathways, taken daily. PT-141 works via melanocortin receptors, taken on-demand. There's no known pharmacokinetic or pharmacodynamic interaction between the two ^[14]. A woman could theoretically use flibanserin daily for baseline modulation and add PT-141 before sexual activity. No trial has tested this, and there are no safety data, so any provider prescribing both would be working from mechanism alone. Testosterone (off-label in women, usually as a transdermal gel or cream) acts on androgen receptors and peripheral tissue. It doesn't interact with melanocortin signaling. Combining testosterone with PT-141 is pharmacologically reasonable but untested. Psychotherapy (cognitive-behavioral therapy for sexual dysfunction, mindfulness-based sex therapy) addresses psychological and relational factors. PT-141 addresses biological signaling. The two are complementary. Several sexual medicine specialists use PT-141 as an adjunct to therapy, especially when desire is low but relationship quality is good ^[15]. No combination has been studied in a controlled trial. If you're considering more than one treatment, work with a provider experienced in female sexual medicine so someone is coordinating and monitoring the whole picture. For a broader look at treatment options, see pt-141 animal studies vs human evidence for the translational research context.

Is PT-141 safe for long-term use?

The longest controlled trial was 24 weeks ^[5]. An open-label extension allowed participants to continue for up to one year. The integrated safety analysis pooled data from 1,127 women across phase 1, 2, and 3 studies, totaling about 4,400 person-months of exposure ^[10]. No new safety signals appeared with longer use. Nausea and flushing remained the most common events, but neither worsened over time. Discontinuation rates were stable after the first few weeks. No cancer signal emerged (melanocortin receptors are expressed in some tumor types, so this was a prespecified safety endpoint). No pattern of cardiovascular events was seen beyond the transient BP rise that occurs with each dose ^[10]. Hyperpigmentation is the theoretical long-term risk. Melanocortin agonists stimulate melanin production. The phase 3 trials didn't find clinically significant darkening, but the follow-up was only one year and the drug was used eight times a month at most. Chronic daily use (not the approved regimen) would carry higher risk. If you're using PT-141 regularly for months, inspect your gums, areolae, and moles every few weeks. Bring any new pigmentation to your provider. Tachyphylaxis (tolerance) is another question. Some G-protein-coupled receptors (the family that includes melanocortin receptors) downregulate with chronic agonist exposure. The trials didn't show a clear pattern of diminishing response over 24 weeks, but the sample was too small and the follow-up too short to rule out tolerance with multi-year use ^[10]. Anecdotal reports are mixed: some women say it keeps working, others report needing it less often once the positive cycle of desire and activity is re-established, and a few say the effect fades. Nobody has data to settle it. Pregnancy and lactation: PT-141 is category X in the old FDA scheme (now relabeled under the Pregnancy and Lactation Labeling Rule). Animal studies showed fetal harm at doses much higher than the human dose, but there are no controlled data in pregnant women ^[4]. If you're trying to conceive or pregnant, don't use PT-141. If you're breastfeeding, the prescribing information recommends against it because melanocortin receptors are expressed in mammary tissue and the drug's passage into milk is unknown. For adults with no contraindications, the current evidence supports safety for at least one year of on-demand use. Longer-term data will come as more women use the drug post-approval.

How does PT-141 compare to flibanserin for women?

Flibanserin (Addyi) is a daily pill approved for the same indication (HSDD in premenopausal women). PT-141 is an on-demand injection. That difference in regimen drives most of the practical distinctions. Mechanism: flibanserin modulates serotonin receptors (5-HT1A agonist, 5-HT2A antagonist) and downstream dopamine and norepinephrine in the prefrontal cortex and hypothalamus ^[16]. PT-141 activates melanocortin receptors in the hypothalamus and limbic system ^[2]. The two drugs don't share a mechanism, and there's no reason to think one mechanism is inherently better. Both aim to shift the balance in central circuits from inhibition to excitation. Efficacy: head-to-head trials don't exist. Both drugs showed statistically significant but modest improvements over placebo in their respective phase 3 programs. A review in Drug and Therapeutics Bulletin noted that effect sizes were small for both and that placebo response rates were high (30-40%), making clinical significance hard to judge ^[17]. Neither produces dramatic results; both help a subset of women. Side effects: flibanserin's main issues are dizziness, somnolence, and nausea, especially if taken with alcohol (the label carries a boxed warning about alcohol interaction and hypotension) ^[16]. PT-141's main issues are nausea and flushing, with transient BP rise rather than drop ^[10]. If you can't tolerate daily nausea or sedation, on-demand PT-141 may be better. If you can't tolerate injections or want something that builds effect over weeks, flibanserin may fit better. Convenience and adherence: flibanserin requires daily adherence, which is hard when the condition being treated is episodic (low desire, by definition, means you're not thinking about sex daily). PT-141's on-demand dosing aligns better with actual sexual activity, but it requires planning (inject 45 minutes ahead) and comfort with self-injection ^[18]. Cost: as of 2024, both branded products are expensive without insurance (several hundred dollars per month). Flibanserin has a generic now, which lowers cost. PT-141 compounded by a 503A or 503B pharmacy typically costs less than branded Vyleesi but more than generic flibanserin. Coverage varies widely by insurer. A clinician's take: if a woman has predictable, infrequent sexual opportunities (say, a partner who travels for work), on-demand PT-141 makes sense. If desire is persistently low seven days a week and she's willing to take a pill daily, flibanserin is worth trying first. If one doesn't work or causes intolerable side effects, the other is a reasonable next step.

Where can women get PT-141 legally and safely?

Three legal pathways exist in the United States: FDA-approved branded Vyleesi, 503A compounded bremelanotide prescribed by a licensed provider, and 503B outsourcing-facility compounded bremelanotide. All three require a prescription. Branded Vyleesi: available at retail pharmacies with a prescription. Your provider writes the script, you pick it up (or have it mailed via pharmacy mail-order). Insurance coverage is inconsistent; many plans don't cover it or require prior authorization. Out-of-pocket cost can exceed $800 per month for eight doses. The manufacturer offers a savings card that may reduce copay, but terms vary. 503A compounding pharmacy: if your provider writes a prescription specifically for you, a state-licensed compounding pharmacy operating under 21 U.S.C. 353a can prepare bremelanotide for you ^[19]. The pharmacy must use a bulk drug substance that is either on the 503A Bulks List (21 CFR 216.23) or nominated and under FDA review ^[20]. As of mid-2024, bremelanotide is nominated but not finalized on the 503A list, so a 503A pharmacy can compound it if the prescriber documents a clinical need and the source API meets USP or equivalent standards ^[21]. Cost is typically lower than branded, often $150 to $400 per month depending on dose and volume. 503B outsourcing facility: these are larger-scale compounders registered with the FDA under 21 U.S.C. 353b. They can produce bremelanotide using bulk substances on the 503B Bulks List (21 CFR 216.24) and distribute without patient-specific prescriptions, though a prescription is still required at the point of dispensing ^[22]. Pricing and availability are similar to 503A. Avoid online vendors selling PT-141 without a prescription, especially those marketing it as a "research chemical" or "not for human use." These products are illegal to sell for human consumption under 21 CFR 201.128 (intended use) and carry serious quality risks (unknown purity, bacterial contamination, wrong concentration) ^[23]. Some sellers ship from overseas; those products have zero regulatory oversight and no recourse if they cause harm. If you're sourcing through a telehealth platform that pairs prescribers with compounding pharmacies, verify that the platform uses licensed U.S. providers and that the pharmacy is state-licensed and (if 503B) FDA-registered. Reputable services will list the pharmacy partner by name and location. If they won't, don't order. Bremelanotide Rx connects women with licensed providers who can evaluate for HSDD and, if appropriate, prescribe compounded bremelanotide filled by a U.S.-based 503A or 503B partner pharmacy. The process is online but includes a real provider review. For more on vetting sources, see pt-141 peptide for sale amazon (short answer: don't) and pt 141 peptide for men near me for related sourcing discussion.

What should women know before trying PT-141?

Set realistic expectations. The phase 3 trials showed that about 1 in 4 women on PT-141 had a clinically meaningful improvement, versus 1 in 6 on placebo ^[6]. That's a real benefit, but it's not universal. Some women notice a clear difference, others feel nothing. Prepare for nausea. It's the most common side effect, and it can be unpleasant enough to ruin the moment you were preparing for. Take the first dose on a day when you have time to see how you react. Don't plan a special evening around dose one. If nausea is mild, you may find it fades with repeat doses (some women report tolerance to nausea over a few weeks) ^[10]. If it's severe, talk to your provider about anti-nausea medication (ondansetron is commonly prescribed) or stopping. Understand that PT-141 treats low desire, not arousal or orgasm problems. If your main issue is difficulty getting physically aroused (vaginal dryness, lack of genital sensation) or reaching orgasm, PT-141 won't directly fix that. It works upstream, in the brain circuits that generate wanting. If you don't want sex in the first place, getting aroused and reaching orgasm are moot. But if you have arousal or orgasm dysfunction without low desire, PT-141 isn't the right tool. Consider whether the problem is relational, situational, or biological. HSDD is diagnosed only when the low desire causes personal distress and isn't better explained by relationship issues, stress, medication side effects, or medical conditions ^[3]. If you're not interested in sex because you're exhausted, your partner is emotionally distant, or you're on an SSRI that flattens libido, PT-141 won't fix the root cause. It's not a substitute for couples therapy, better sleep, or adjusting a medication. Check your cardiovascular status. If you have a history of heart disease, stroke, or uncontrolled high blood pressure, PT-141 may not be safe ^[11]. The transient BP spike is usually harmless in healthy women but can be risky if your baseline pressure is already high or your vessels are compromised. Get clearance from your cardiologist or primary care provider before starting. Plan logistics. You inject 45 minutes before sexual activity. That requires some forethought and privacy. If spontaneity is important to you, the 45-minute window might feel awkward. Some couples build the injection into foreplay (one partner helps with the injection, you use the waiting time for non-genital intimacy). Others find it clinical and off-putting. Think about whether you can integrate it into your routine. Finally, track your response. Keep notes for the first month: did you feel an increase in desire? Was the timing right? How bad was the nausea? Did you actually have sex, and was it more satisfying than usual? Subjective changes in desire are easy to misremember. If after four to six doses you don't see a difference, bring that data to your provider and discuss whether to continue, try a different treatment, or focus on non-pharmacologic approaches.

Frequently asked questions

Does PT-141 work immediately for women?

No. PT-141 takes 45 to 60 minutes to reach peak concentration after subcutaneous injection, and subjective effects on desire may take an hour or more. Inject at least 45 minutes before anticipated sexual activity. Some women report effect as early as 30 minutes, others find it peaks around 90 minutes. It is not an instant-arousal drug; it modulates central desire circuits that unfold over the course of an hour.

Can PT-141 be used by postmenopausal women?

The FDA approval is for premenopausal women, but subgroup analyses from phase 3 trials showed similar efficacy in postmenopausal women. Off-label use is common in clinical practice. If you're postmenopausal and interested, discuss it with your provider. The mechanism (central melanocortin signaling) does not require ovarian hormones, so there's no obvious biological reason it would fail after menopause.

How often can you use PT-141 for low desire?

The approved maximum is one dose per 24 hours and no more than eight doses per calendar month. The limit is based on the trial protocol and reflects both efficacy data (more frequent use wasn't tested) and safety caution (cumulative exposure to a drug that transiently raises blood pressure and causes nausea). Most women in practice use it less often, perhaps two to four times a month.

Does PT-141 cause weight gain or loss in women?

Weight was not a primary outcome in the HSDD trials, but exploratory analyses found no consistent pattern. A phase 1 study in obese women noted modest weight loss (mean 1.5 kg over 12 weeks) with daily bremelanotide dosing, possibly via melanocortin effects on appetite and metabolism, but that regimen is not the approved use. On-demand dosing at 1.75 mg has no documented impact on weight.

Can you drink alcohol while using PT-141?

There is no formal alcohol contraindication for PT-141 (unlike flibanserin, which has a boxed warning about alcohol and hypotension). The trials did not explicitly test alcohol co-administration, so safety data are limited. Because PT-141 can cause transient blood pressure changes and nausea, and alcohol can do the same, combining them may worsen side effects. Use caution, and consider skipping alcohol the evening you inject until you know how you tolerate the drug.

Is PT-141 the same as Viagra for women?

No. Viagra (sildenafil) increases blood flow to the genitals by inhibiting phosphodiesterase-5. It treats erectile dysfunction in men and has been tried in women with mixed results. PT-141 works centrally by activating melanocortin receptors in the brain to increase desire. It does not directly affect genital blood flow. The comparison is common but misleading; the two drugs have different mechanisms, different indications, and different side-effect profiles.

Does PT-141 help with orgasm or arousal problems?

PT-141 is approved specifically for low desire (HSDD). It was not studied for arousal disorder or anorgasmia. The phase 3 trials measured desire and distress as primary endpoints; arousal and orgasm were secondary and showed less consistent improvement. If your main problem is difficulty getting physically aroused or reaching orgasm, PT-141 is not the best choice. It works upstream in the motivation circuitry, not downstream in the arousal reflex.

Can PT-141 be combined with testosterone for women?

There are no studies testing the combination, but the mechanisms are independent (melanocortin vs. androgen receptor signaling). Some providers prescribe both off-label, using testosterone for baseline androgenic support and PT-141 for on-demand desire boost. No safety data exist, so any combination would be empirical. If you're considering both, work with a provider experienced in female sexual medicine who can monitor the whole regimen.

How long does PT-141 stay in your system?

Bremelanotide has a plasma half-life of approximately 2 to 3 hours. Most of the drug is cleared within 12 to 24 hours. However, subjective effects on desire may last longer, likely because receptor binding and downstream signaling persist after the drug is eliminated from the blood. Some women report feeling the effect for several hours after injection.

Does PT-141 cause skin darkening in women?

Hyperpigmentation (darkening of skin, gums, or existing moles) is a theoretical risk because melanocortin receptors regulate melanocyte activity. The phase 3 trials did not report clinically significant hyperpigmentation, but the follow-up was only 24 weeks and dosing was intermittent (up to eight times per month). If you use PT-141 for many months, inspect your gums, areolae, and moles regularly. Report any new pigmentation to your provider.

Can PT-141 be used during pregnancy or breastfeeding?

No. PT-141 is contraindicated in pregnancy. Animal studies showed fetal harm at high doses, and there are no controlled data in pregnant women. If you're trying to conceive, pregnant, or breastfeeding, do not use PT-141. The prescribing information recommends against use during lactation because passage into breast milk and effects on the infant are unknown.

Does insurance cover PT-141 for women?

Coverage is inconsistent. Some insurers cover branded Vyleesi with prior authorization, many do not. Compounded bremelanotide from 503A or 503B pharmacies is even less likely to be covered, though some patients submit superbills for reimbursement. Out-of-pocket cost for branded Vyleesi can exceed $800 per month; compounded versions typically cost $150 to $400 per month. Check with your insurer and ask the prescribing provider or pharmacy about manufacturer savings programs.

What is the best injection site for PT-141 in women?

The FDA-approved sites are the abdomen (at least two inches away from the navel) and the front of the thigh. Both are subcutaneous (into the fat layer, not muscle). The abdomen is slightly faster-absorbing. Rotate sites each time to avoid irritation or lipohypertrophy (lumps under the skin from repeated injections in the same spot). Use a clean technique: alcohol prep, let it dry, pinch the skin, insert at a 45-degree angle, inject slowly.

Does PT-141 interact with antidepressants?

There are no known pharmacokinetic interactions between PT-141 and SSRIs, SNRIs, or other antidepressants. Melanocortin signaling is independent of serotonin or norepinephrine reuptake. However, many antidepressants (especially SSRIs) cause sexual side effects, including low desire, and PT-141 may not fully overcome that. If you're on an antidepressant and considering PT-141 for low desire, discuss whether switching or adjusting the antidepressant might be more effective.

Sources

1. Drugs (PMID 31429064): Bremelanotide received FDA approval in June 2019 for acquired, generalized HSDD in premenopausal women.
2. CNS Spectrums (PMID 33455598): Bremelanotide binds to melanocortin MC3 and MC4 receptors in the hypothalamus and other brain regions regulating sexual response.
3. Journal of Midwifery & Women's Health (PMID 34510696): HSDD reflects an imbalance between excitatory and inhibitory neural pathways in the brain.
4. The Annals of Pharmacotherapy (PMID 31893927): The approved Vyleesi autoinjector delivers 1.75 mg in a single-dose subcutaneous injection.
5. Obstetrics and Gynecology (PMID 31599840): Two phase 3 RECONNECT trials enrolled 1,247 premenopausal women with HSDD and showed statistically significant improvements in desire and distress scores with bremelanotide versus placebo.
6. The Journal of Sexual Medicine (PMID 31277966): Responder analysis showed 24.5% of bremelanotide users had clinically meaningful improvement versus 17.0% on placebo.
7. Journal of Women's Health (PMID 35230162): Prespecified subgroup analyses found similar effect sizes across age, menopausal status, BMI, and whether HSDD was acquired or lifelong.
8. Journal of Sex Research (PMID 36809187): A reanalysis noted the effect size for desire endpoint was small (Cohen's d ≈ 0.22) and questioned clinical significance.
9. Journal of Sex Research (PMID 33678061): Critics noted high placebo response rates (about 35% on some measures) in the phase 3 trials.
10. Journal of Women's Health (PMID 35147466): Integrated safety analysis showed 40.0% nausea with bremelanotide versus 12.5% placebo; 20.3% flushing versus 2.8% placebo; no new safety signals with longer use.
11. Medicina (PMID 35630054): Women with uncontrolled hypertension were excluded from trials; the drug is not recommended for those with cardiovascular disease.
12. Expert Opinion on Pharmacotherapy (PMID 36242769): Peak plasma concentration occurs around 60 minutes after injection; half-life is about 2 to 3 hours.
13. The Urologic Clinics of North America (PMID 35428435): The melanocortin system operates independently of estrogen and progesterone, though those hormones modulate sexual response through parallel pathways.
14. Current Psychiatry Reports (PMID 35102537): Flibanserin works via serotonin and dopamine pathways; no known interaction with bremelanotide's melanocortin mechanism.
15. Neurology International (PMID 35076581): Several sexual medicine specialists use PT-141 as an adjunct to psychotherapy when desire is low but relationship quality is good.
16. Current Opinion in Obstetrics & Gynecology (PMID 36036468): Flibanserin modulates 5-HT1A agonism and 5-HT2A antagonism with a boxed warning about alcohol interaction and hypotension.
17. Drug and Therapeutics Bulletin (PMID 34642243): Review noted both bremelanotide and flibanserin showed small effect sizes with high placebo response rates.
18. Clinical Obstetrics and Gynecology (PMID 39846877): On-demand PT-141 dosing aligns better with actual sexual activity but requires planning and comfort with self-injection.
19. 21 U.S.C. 353a (Cornell Law): Federal statute governing 503A compounding pharmacies and patient-specific prescriptions.
20. 21 CFR 216.23 (eCFR): The final 503A Bulks List specifying bulk drug substances permissible for compounding under 503A.
21. FDA bulk drug substances used in compounding under 503A: As of mid-2024, bremelanotide is nominated but not finalized on the 503A list.
22. 21 CFR 216.24 (eCFR): The 503B Bulks List specifying bulk drug substances permissible for 503B outsourcing facilities.
23. 21 CFR 201.128 (eCFR): Regulation defining intended uses for drugs, making sale of research chemicals for human use illegal.